ZYME|Zymeworks Inc|Price:24.180|Chg%:-0.51

More Details of Zymeworks Inc Company

Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.

Zymeworks Inc Info



Ticker SymbolZYME

Company nameZymeworks Inc

IPO dateJun 24, 2019

CEOGalbraith (Kenneth H)

Number of employees280

Security typeOrdinary Share

Fiscal year-endJun 24

Address108 Patriot Drive, Suite A

CityMIDDLETOWN

Stock exchangeNASDAQ OMX - NASDAQ BASIC

CountryUnited States of America

Postal code19709

Phone13022748744

Websitehttps://www.zymeworks.com/

Ticker SymbolZYME

IPO dateJun 24, 2019

CEOGalbraith (Kenneth H)

Company Executives of Zymeworks Inc



Name

Name/Position

Position

Shareholding

Change

Mr. Kenneth H. (Ken) Galbraith

Chairman of the Board, President, Chief Executive Officer

--

Dr. Susan M. (Sue) Mahony, Ph.D.

Lead Independent Director

--

Dr. Kelvin M. Neu ,M.D.

Independent Director

--

Dr. Paul A. Moore, Ph.D.

Chief Scientific Officer

--

Mr. Carlos E. Campoy

Independent Director

--

Dr. Alessandra Cesano, M.D., Ph.D.

Independent Director

--

Mr. Scott Platshon

Acting Chief Investment Officer

--

Ms. Leone D. Patterson, CPA

Chief Financial Officer, Chief Business Officer, Executive Vice President

--

Dr. Jeffrey Smith, M.D.

Executive Vice President, Chief Medical Officer

--

Mr. Oleg Nodelman

Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Mr. Kenneth H. (Ken) Galbraith

Chairman of the Board, President, Chief Executive Officer

--

Dr. Susan M. (Sue) Mahony, Ph.D.

Lead Independent Director

--

Dr. Kelvin M. Neu ,M.D.

Independent Director

--

Dr. Paul A. Moore, Ph.D.

Chief Scientific Officer

--

Mr. Carlos E. Campoy

Independent Director

--

Dr. Alessandra Cesano, M.D., Ph.D.

Independent Director

--

Revenue Breakdown

Relevant data have not been disclosed by the company yet.

Relevant data have not been disclosed by the company yet.

By Business

By Region

Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Sat, Feb 21

Shareholders

Shareholder Types

Shareholders

Proportion

EcoR1 Capital, LLC

31.15%

Rubric Capital Management LP

7.80%

BVF Partners L.P.

5.34%

BlackRock Institutional Trust Company, N.A.

4.67%

Perceptive Advisors LLC

4.42%

Other

46.62%

Shareholders

Proportion

EcoR1 Capital, LLC

31.15%

Rubric Capital Management LP

7.80%

BVF Partners L.P.

5.34%

BlackRock Institutional Trust Company, N.A.

4.67%

Perceptive Advisors LLC

4.42%

Other

46.62%

Shareholder Types

Shareholders

Proportion

Investment Advisor/Hedge Fund

43.78%

Investment Advisor

25.88%

Hedge Fund

19.05%

Research Firm

4.68%

Private Equity

4.42%

Individual Investor

1.26%

Pension Fund

0.29%

Bank and Trust

0.26%

Venture Capital

0.13%

Other

0.25%

Institutional Shareholding



Updated: Wed, Jan 21

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2026Q4

333

74.80M

105.96%

--

2025Q4

408

76.12M

101.71%

-5.88M

2025Q3

390

74.41M

99.43%

-2.56M

2025Q2

383

76.90M

102.73%

+2.83M

2025Q1

400

71.70M

97.61%

-1.37M

2024Q4

389

68.69M

99.73%

-8.79M

2024Q3

388

74.13M

105.03%

-25.13M

2024Q2

387

74.77M

106.29%

-27.88M

2024Q1

389

74.54M

106.20%

-28.73M

2023Q4

388

72.09M

103.65%

-29.69M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

EcoR1 Capital, LLC

22.97M

30.69%

--

Nov 16, 2025

Rubric Capital Management LP

4.71M

6.29%

--

Sep 30, 2025

BVF Partners L.P.

3.94M

5.26%

-370.29K

-8.59%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

3.12M

4.17%

+11.88K

+0.38%

Sep 30, 2025

Perceptive Advisors LLC

2.09M

2.79%

+815.39K

+63.94%

Sep 30, 2025

Morgan Stanley & Co. LLC

3.92M

5.23%

+295.26K

+8.15%

Sep 30, 2025

The Vanguard Group, Inc.

2.15M

2.87%

-310.26K

-12.63%

Sep 30, 2025

DWS Investments UK Limited

1.44M

1.93%

+135.00

+0.01%

Sep 30, 2025

Related ETFs



Updated: Sat, Dec 6

Name

Proportion

Tema Oncology ETF

2.25%

Virtus LifeSci Biotech Clinical Trials ETF

0.99%

ProShares Ultra Nasdaq Biotechnology

0.24%

iShares Micro-Cap ETF

0.18%

Federated Hermes MDT Small Cap Core ETF

0.15%

WisdomTree US SmallCap Quality Growth Fund

0.15%

SPDR S&P International Small Cap ETF

0.14%

Invesco Nasdaq Biotechnology ETF

0.14%

iShares Biotechnology ETF

0.12%

iShares MSCI USA Small-Cap Min Vol Factor ETF

0.12%

Tema Oncology ETF

Proportion2.25%

Virtus LifeSci Biotech Clinical Trials ETF

Proportion0.99%

ProShares Ultra Nasdaq Biotechnology

Proportion0.24%

iShares Micro-Cap ETF

Proportion0.18%

Federated Hermes MDT Small Cap Core ETF

Proportion0.15%

WisdomTree US SmallCap Quality Growth Fund

Proportion0.15%

SPDR S&P International Small Cap ETF

Proportion0.14%

Invesco Nasdaq Biotechnology ETF

Proportion0.14%

iShares Biotechnology ETF

Proportion0.12%

iShares MSCI USA Small-Cap Min Vol Factor ETF

Proportion0.12%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Splits



Date

Ex-dividend Date

Type

Ratio

No Data

Date

Ex-dividend Date

Type

Ratio

No Data